Keyword: Kalydeco

Vertex has cancelled plans to test an investigational triple combo at several sites in France.

Vertex is ready to do some deals, CEO Jeffrey Leiden said Monday, and he's shopping beyond cystic fibrosis. CRISPR, for instance.

Stepped-up competition and insurer pushback aren't going away, but some are better able to handle it—and could emerge as top M&A targets.

Last year, the FDA nixed Vertex’s bid to expand Kalydeco to patients with specific mutations in the CFTR gene. On Wednesday, though, the drugmaker finally got what it wanted.

Vertex started tying compensation more closely to company performance last year, and it showed in CEO Jeff Leiden's 2016 pay.

Vertex has a new cystic fibrosis combo prospect it hopes can fare better than Orkambi—but the question is, how much?

Vertex is consolidating its R&D operations to three sites and shuttering one facility in Canada in a move that will claim 70 jobs there.

Growth of Vertex’s cystic fibrosis combo Orkambi took a hit last year, and for this year, projections are coming in below where analysts thought they’d be.

Vertex socked more money into its Orkambi marketing after the combo CF med's launch lagged. Now, that's paying off--and Vertex is proving itself undeterred in developing new cocktails based on VX-661, which failed a trial in August.